TACSTD2 and cancer: Consistent with previous studies, repeated PIT with TROP2‐IR700 enhanced treatment effects without adverse effects in vivo.34 As TROP2 is overexpressed in many types of cancer, PIT utilizing TROP2‐IR700 solely or in combination with other mAb‐IR700 could be an effective platform for multiple tumor types.